The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Optometry
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Campaigns & Insights
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2026 / October / The Evolution of Dry Eye Management
Anterior Segment Discussion Optometry

The Evolution of Dry Eye Management

Innovations shaping clinical practice

By Jacob Lang 10/21/2026 4 min read

Share

  • Full Article
  • Summary
  • Takeaways
  • Quiz
  • Poll
Objective:

The article examines the objective, findings, and clinical context described in The Evolution of Dry Eye Management.

Approach:
  • Personalized assessment: Learn about patients’ symptoms, frustrations, and goals; use the SPEED survey to quantify symptoms and track change; and correlate reported experiences with examination findings.
  • Diagnostic testing: The author describes assessing tear osmolarity, MMP-9, tear volume, and tear breakup time to inform management choices.
  • Combined therapies: The author describes using nutraceuticals, topical drops, tear-drainage occlusion, thermal gland expression, and intense pulsed light according to the patient’s condition.
Key Findings:
  • The article presents dry eye as a chronic condition without a single therapy that works for everyone.
  • The author describes HydroEye as a supplement intended to support meibum and help control inflammation, and reports seeing improvements in patients using nutraceuticals.
  • The author describes perfluorohexyloctane (Miebo) as a waterless drop intended to reduce evaporation and provide lubrication for evaporative dry eye or meibomian gland dysfunction.
  • Acoltremon (Tryptyr) is described as stimulating corneal cold receptors to trigger tear production; the author reports using it for aqueous deficiency, including cases with MGD.
  • The author describes Lacrifill gel as blocking tear drainage, TearCare as providing thermal expression of meibomian glands, and IPL as targeting inflammation, particularly in patients with rosacea.
Interpretation:

The article advocates matching treatment choices to patients’ reported symptoms and clinical findings, often combining newer therapies with established approaches. Treatment descriptions and reported outcomes reflect the author’s clinical perspective.

Limitations:
  • The context is a practitioner’s perspective and does not provide comparative trial results or detailed evidence for most treatment claims.
  • The article does not report patient numbers, outcome measures, or follow-up data for the author’s clinical observations.
Sources:
  • Article context provided by the user

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Your Privacy Choices
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: